A

Armata Pharmaceuticals Inc
AMEX:ARMP

Watchlist Manager
Armata Pharmaceuticals Inc
AMEX:ARMP
Watchlist
Price: 6.28 USD -1.41% Market Closed
Market Cap: 228.7m USD

Armata Pharmaceuticals Inc
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Armata Pharmaceuticals Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Interest Income Expense
$7.5m
CAGR 3-Years
807%
CAGR 5-Years
N/A
CAGR 10-Years
-13%
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$2.6B
CAGR 3-Years
-5%
CAGR 5-Years
-4%
CAGR 10-Years
-7%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$694m
CAGR 3-Years
22%
CAGR 5-Years
9%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.9B
CAGR 3-Years
-30%
CAGR 5-Years
-25%
CAGR 10-Years
-18%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$476.3m
CAGR 3-Years
N/A
CAGR 5-Years
32%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$1.4B
CAGR 3-Years
N/A
CAGR 5-Years
40%
CAGR 10-Years
N/A
No Stocks Found

Armata Pharmaceuticals Inc
Glance View

Market Cap
227.3m USD
Industry
Biotechnology

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

ARMP Intrinsic Value
2.81 USD
Overvaluation 55%
Intrinsic Value
Price
A

See Also

What is Armata Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
7.5m USD

Based on the financial report for Jun 30, 2025, Armata Pharmaceuticals Inc's Interest Income Expense amounts to 7.5m USD.

What is Armata Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-13%

The average annual Interest Income Expense growth rates for Armata Pharmaceuticals Inc have been 807% over the past three years , and -13% over the past ten years .

Back to Top